Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

This trial tests whether adding pemigatinib — a targeted drug that blocks a pathway called FGFR — after standard induction chemotherapy can improve outcomes in adults newly diagnosed with intermediate- or high-risk acute myeloid leukemia (AML) without certain common genetic mutations. **You may be eligible if...** - You are 18 or older with newly diagnosed AML - Your AML does not have FLT3 mutations and is classified as intermediate or adverse risk by established leukemia guidelines - Your general health allows you to tolerate treatment (ECOG 0–2) - You are willing to consent to a bone marrow biopsy before starting standard chemotherapy **You may NOT be eligible if...** - You have favorable-risk AML or FLT3-mutated AML - Your AML has spread to the brain - You have received recent anti-cancer therapy without adequate recovery - You are pregnant or unwilling to use contraception Talk to your doctor to see if this trial is right for you.